forbes article, page-13

LOL, funny what sort of article gets written when the writer looks for facts to back up the spin of the company.

And doesnt look like a good day for UNIS on the US market. Cant help but wonder when that ATM is going to get tapped again. The company must be running pretty low on funds.

And I think for a vaccine 13 years is understandable. For a syringe I think it is perfectly reasonable to start questioning whether the market actually wants the product, especially when a very similar product in Unitract was not commercially viable. I think 3 years post IA will be my point of no return, so in another 20 months if nothing has been delivered re Unifill than I think it will be safe to be concerned. Frankly, my reservations escalated at the 2 year mark